Skip to main content

Table 1 Patient characteristics

From: Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study

 

All patients screened (n = 105)

No fibrinolysis resistance (LT < 300) (n = 47)

Fibrinolysis resistance (LT > 300) (n = 58)

COVID + ve (n = 69)**

COVID − ve (n = 36)

Demographic and treatment variables

Age

62 [45–71]

63 [54–71]

59 [41–72]

64 [52–71]

59 [40–71]

Gender, female (%)

37 (35%)

19 [40%]

17 (29%)

26 (38%)

11 (31%)

LOS ICU

6.7 [2.7–15]

7.4 [3.3–13]

6.2 [2.3–16]

6.7 [2.8–12.9]

6.4 [2.2–19]

APACHE III

66 [49–81]

69 [56–81]

59 [46–80]

66 [49–78]

67 [53–81]

ICU mortality

19 (18%)

11 (23%)

8 (14%)

13 (20%)

6 (17%)

Hospital mortality

26 (25%)

13 (28%)

13 (22%)

19 (28%)

7 (19%)

Invasive ventilation

59 (56%)

26 (55%)

31 (53%)

31 (45%)

22 (61%)

P/F ratio

152 [122–258]

148 [111–202]

158 [132–319]

133 [111–154]

256 [174–360]

Inotropes

34 (32%)

16 (34%)

18 (31%)

17 (25%)

13 (36%)

DVT prophylaxis *

103 (98%)

46 (98%)

57 (98%)

67 (97%)

36 (100%)

Primary diagnostic category

Respiratory

     

  COVID-19

45 (58%)

21 (45%)

26 (45%)

48 (69%)

0

  Non-COVID-19

4 (4%)

2 (4%)

2 (3%)

0

5 (14%)

Cardiac

8 (8%)

3 (6%)

5 (9%)

3 (4%)

5 (14%)

Gastrointestinal

8 (8%)

3 (6%)

5 (9%)

3 (4%)

5 (14%)

Neurological

6 (6%)

3 (6%)

3 (5%)

3 (4%)

2 (6%)

Renal

5 (5%)

4 (9%)

1 (2%)

4 (6%)

1 (3%)

Sepsis

15 (14%)

7 (15%)

8 (14%)

3 (4%)

10 (28%)

Trauma

10 (10%)

2 (4%)

8 (14%)

2 (3%)

8 (22%)

Other

4 (4%)

2 (4%)

0

3 (4%)

0

Coagulation variables

Platelet count

210 [148–304]

200 [164–253]

232 [133–321]

211 [158–310]

194 [133–291]

PT

13 [13–15]

13 [12–14]

14 [13–15]

13 [13–15]

14 [13–15]

aPTT

29 [26–34]

29 [25–33]

30 [27–34]

29 [26–33]

30 [27–34]

INR

1.2 [1.1–1.3]

1.1 [1.0–1.2]

1.2 [1.1–1.3]

1.1 [1.1–1.3]

1.2 [1.1–1.4]

Fibrinogen

5.0 [3.8–6.4]

4.7 [3.7–5.8]

5.3 [4.0–7.0]

5.1 [3.8–6.3]

4.5 [3.6–6.0]

ClotPro variables

FIB-test A10

27 [21–31]

24 [18–27]

30 [26–32]

26 [20–30]

29 [22–32]

EX-test A10

65 [59–67]

63 [57–65]

67 [60–69]

65 [58–67]

66 [60–68]

Platelet A10

38 [34–40]

38 [35–41]

37 [34–39]

38 [35–39]

38 [33–40]

TPA-test MCF

44 [36–53]

38 [29–43]

52 [46–59]

42 [33–49]

47 [38–56]

TPA-test LT

308 [268–418]

263 [195–274]

398 [331–530]

302 [252–364]

338 [270–432]

  1. Values are medians with interquartile ranges in [brackets] or counts with percentage in (parentheses)
  2. LOS ICU length of stay in intensive care unit, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, P/F ratio ratio between arterial partial pressure (P) of oxygen and fraction (F) inspired oxygen, DVT deep venous thrombosis, COVID-19 coronavirus disease of 2019, PT prothrombin time, aPTT activated partial thromboplastin time, INR international normalised ratio, FIB-test A10 clot amplitude at 10 min, surrogate measure for functional fibrinogen, EX-test A10 clot amplitude at 10 min for testing the extrinsic coagulation pathway, Platelet A10 amplitude at 10 min for the calculated contribution of platelets, TPA-test MCF maximum clot firmness for the fibrinolysis activation test, TPA-test LT time to lysis down to 50% of the clot amplitude by the fibrinolysis activation test
  3. *Includes prophylactic dosing of heparin (5000 units twice daily) or enoxaparin (40 mg daily) and/or calf compressors
  4. **This group includes patients with an incidental finding of a positive SARS-Cov2 PCR test while this was not the primary reason for admission to ICU
Back to article page

Critical Care

ISSN: 1364-8535